RESEARCH

A $900 Million Shot: Halozyme Targets Smoother Drug Delivery

Halozyme’s $900M Elektrofi deal aims to speed up and simplify injectable biologic treatments

10 Oct 2025

A $900 Million Shot: Halozyme Targets Smoother Drug Delivery

Halozyme, a California-based biotechnology firm, announced on October 1st that it will acquire Elektrofi, a Boston start-up specialising in concentrated biologic formulations, for up to $900m. The transaction, approved by both boards, includes $750m in cash and a further $150m tied to milestones. It is expected to close by the end of 2025, subject to regulatory clearance.

The purchase expands Halozyme’s hold on the growing market for subcutaneous delivery of complex drugs. Elektrofi’s “Hypercon” technology allows high-dose biologics to be injected under the skin rather than infused intravenously over several hours. Combined with Halozyme’s own ENHANZE platform, which enables large-molecule drugs to be absorbed more easily, the company hopes to offer patients with chronic illnesses faster and more convenient treatment options, possibly even at home.

Analysts call the deal strategic rather than speculative. “This move positions Halozyme to deepen its leadership in subcutaneous biologics,” said a GlobalData analyst. “The technology shows promise, but its success will hinge on formulation stability, manufacturing scale-up and regulatory progress.”

Elektrofi, backed by Novo Holdings and Omega Funds, has partnerships with major biopharma companies testing advanced delivery systems. Halozyme’s acquisition thus continues a trend toward collaboration and patient-centric care.

The transaction also reflects a wider industry shift: as biologics grow more potent, firms are racing to make them easier to deliver. Turning complex therapies into quick injections could reduce strain on hospitals and broaden access for patients. Yet the science remains tricky; concentrated formulations risk instability and high production costs.

If integration succeeds, Halozyme may find itself at the forefront of a new generation of injectable biologics, bringing treatments not just closer to the bloodstream but closer to home.

Latest News

  • 14 Nov 2025

    Can Tiny Injections Replace Big Infusions
  • 12 Nov 2025

    AI Redesigns How America Makes Its Medicines
  • 11 Nov 2025

    Allies in Innovation: The Rise of Drug Delivery Partnerships
  • 7 Nov 2025

    Nanoform and Takeda Bet on Miniature Science

Related News

Exterior view of Halozyme building featuring logo above main entrance.

INNOVATION

14 Nov 2025

Can Tiny Injections Replace Big Infusions
Robotic arm in a bright automated laboratory used for advanced pharmaceutical or biotech processes.

TECHNOLOGY

12 Nov 2025

AI Redesigns How America Makes Its Medicines
Allies in Innovation: The Rise of Drug Delivery Partnerships

PARTNERSHIPS

11 Nov 2025

Allies in Innovation: The Rise of Drug Delivery Partnerships

SUBSCRIBE FOR UPDATES

By submitting, you agree to receive email communications from the event organizers, including upcoming promotions and discounted tickets, news, and access to related events.